Microbix Biosystems (MBXBF) welcomed the College of America Pathologists as a customer for Microbix quality assessment products for use in CAP clinical laboratory proficiency-testing programs, also commonly known as External Quality Assessments. Following a merit-driven selection process and customary confidential supply and quality agreements, Microbix has begun to supply its QAPs for supporting CAP PT/EQA programs. The identity of the CAP PT/EQA programs that Microbix QAPs are now supporting must remain confidential due to the CAP’s need to blind participating clinical laboratories as to what patient-sample mimetics are being used to assess their testing proficiency. That being said, Microbix is pleased to confirm that multiple SKUs of its QAPs have been provided to CAP and, in turn, are being used at clinical labs that are subscribers to CAP PT/EQA programs. Microbix aims to support multiple CAP PT/EQA programs, expand its product offerings, and strengthen client relationships throughout fiscal 2026 and beyond.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBXBF:
- Microbix to Release Q1 2026 Results and Host Investor Webinar on February 12
- Microbix Unveils FFPE-Simulated QC Platform to Standardize Molecular Pathology Testing
- Microbix Biosystems presents Molecular Pathology platform results
- Microbix Tightens EBITDA Disclosure After OSC Review
- Microbix Biosystems updates investor presentation in response to OSC
